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Abstract: Increasing rates of antimicrobial resistance among strains of Streptococcus, 
Staphylococcus, and Enterococcus spp. have been widely documented. At least 50% of noso-
comial Staphylococcus aureus infections in intensive care units in the US and UK are due 
methicillin-resistant S. aureus (MRSA). Drug resistance is not conﬁ  ned to hospitals, and com-
munity-acquired MRSA (CA-MRSA) strains are now common causes of complicated skin and 
soft-tissue infections (cSSTIs) in many regions. Dalbavancin is a novel parenterally administered 
semisynthetic lipoglycopeptide similar to the naturally produced glycopeptides vancomycin and 
teicoplanin. Dalbavancin features a multifaceted mechanism of action that inhibits bacterial cell 
wall formation by two different mechanisms that enhances its activity against a wide range of 
gram-positive bacteria including staphylococci, streptococci, enterococci, and some anaerobes. 
Additionally, dalbavancin possesses unique pharmacokinetic properties, the most signiﬁ  cant of 
which is a long terminal half-life that allows for once weekly dosing. This attribute may prove 
to yield clinical and cost beneﬁ  t. Overall, clinical trials indicate that dalbavancin is a safe, well-
tolerated, and effective antimicrobial agent. In the largest investigation evaluating dalbavancin 
for the treatment of cSSTIs, it appeared to be as effective as linezolid. Dalbavancin, which is 
expected to receive FDA approval in 2008, appears to be a promising new antimicrobial agent 
for the treatment of cSSTIs.
Introduction
The increased incidence of serious infections caused by resistant gram-positive 
pathogens has encouraged the development of new antimicrobial agents. Compli-
cated skin and soft-tissue infections (cSSTIs) are broadly deﬁ  ned as infections of 
the deep soft-tissues or that require surgical intervention beyond simple incision 
and drainage of purulent ﬂ  uid collections. Gram-positive pathogens, in particular 
Staphylococcus aureus and the β-hemolytic streptococci, are the most frequently 
implicated organisms in cSSTIs; however, in the appropriate clinical setting, other 
organisms including enterococci may contribute to pathogenesis (Doern et al 1999; 
CDC 2003; Lipsky et al 2004). Increasing rates of antimicrobial resistance among 
strains of Streptococcus, Staphylococcus, and Enterococcus spp. have been widely 
documented. The prevalence of methicillin-resistant S. aureus (MRSA) may vary 
between communities or regions; however, currently 50% of S. aureus isolates 
causing nosocomial infections in U.S. intensive care units are MRSA and similar 
rates for nosocomial S. aureus bacteremia are reported in the U.K. (Voss et al 1994; 
Styers et al 2006). MRSA has expanded beyond its historical niche of hospital-
acquired infections in patients with traditional risk factors and has now become a 
major pathogen within the community (Fridkin et al 2005; Zetola et al 2005; King 
et al 2006; Moran et al 2006). Additionally, within certain geographic centers, 
community-associated MRSA (CA-MRSA) strains appear to be transitioning into 
nosocomial pathogens (Seybold et al 2006; Maree et al 2007).Therapeutics and Clinical Risk Management 2008:4(1) 32
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In the late 1980s, vancomycin-resistant enterococci 
(VRE) were the ﬁ  rst pathogens identiﬁ  ed with glycopeptide 
resistance (Moellering 1998). Staphylococci with reduced 
susceptibility to vancomycin, termed vancomycin-
intermediate S. aureus (VISA), were ﬁ  rst reported in Japan 
and closely thereafter in the US (Hiramatsu et al 1997; 
Sieradzki et al 1999). Not long after, the ﬁ  rst report of 
vancomycin-resistant S. aureus (VRSA) was described 
in a patient from Michigan; since that time, several other 
strains of VRSA have emerged (Sievert et al 2002; Chang 
et al 2003a). Besides VRSA and VISA, S. aureus strains 
with heteroresistance to vancomycin (hVISA) have also 
been described. These organisms are problematic due to 
subpopulations with reduced susceptibility to vancomycin 
in vitro that appear to increase the risk of clinical failure 
(Charles et al 2004). While the full clinical signiﬁ  cance of 
hVISA remains unclear and both VISA as well as VRSA 
remain rare occurrences, these developments and trends are 
clinically troublesome (Deresinksi 2007).
In the face of increasing resistance in S. aureus, traditional 
empiric therapy with penicillinase-resistant penicillins and 
vancomycin has become less reliable (Deresinksi 2007). 
Additionally, increased scrutiny of vancomycin tissue pen-
etration and dosing methods has fostered debate over its role 
as the cornerstone for serious cSSTIs infections caused by 
resistant gram-positive organisms (Lipsky et al 2004; Stevens 
et al 2005; Skhirtladze et al 2006; Mohr and Murray 2007; 
Deresinski 2007). Vancomycin has long been the workhorse 
antimicrobial therapy for resistant gram-positive infections; 
however, increasing resistance in cSSTI pathogens and 
increasing reports of clinical failures have necessitated the 
search for alternative agents.
Dalbavancin is a novel parenterally administered semisyn-
thetic lipoglycopeptide developed to combat infections caused 
by resistant gram-positive pathogens. Dalbavancin exhibits 
potent in vitro bactericidal activity against gram-positive 
pathogens including MRSA, VISA, and non-VanA strains 
of VRE; and clinical data indicate that dalbavancin is a safe, 
effective, and well-tolerated therapy for cSSTIs (Seltzer et al 
2003; Streit et al 2004; Jauregui et al 2005). US Food and Drug 
Administration approval is expected in 2007. This review of 
the English medical literature covers the pharmacologic and 
microbiological properties of dalbavancin with an emphasis 
on the available clinical data for the treatment of cSSTI.
Pharmacology
Dalbavancin (formerly BI397) is a novel semisynthetic 
lipoglycopeptide, and is a member of the glycopeptide 
antimicrobials which include: vancomycin and teicoplanin, 
and the investigational agents oritavancin and televancin. 
Due to its poor oral bioavailability, it is available only in 
an intravenous formulation (Van Bambeke et al 2004). 
Dalbavancin is derived from MDL 62,476 (formerly 
A-40926) which is a naturally occurring teicoplanin-like 
product of the actinomycete Nonomuraea spp ATCC 
39727 (Beltrametti et al 2003; Technichova et al 2004). The 
mechanism of action of dalbavancin against gram-positive 
organisms is similar to other glycopeptides. Dalbavancin 
disrupts bacterial cell wall synthesis by binding to the 
C-terminal D-alanyl-D-alanine of growing peptidoglycan 
chains and consequently prevents transpeptidation (Finch 
and Eliopoulus 2005). Unlike naturally occurring glyco-
peptides, however, dalbavancin has the ability to dimerize 
and anchor into the bacterial membrane which improves 
stabilization and increases its afﬁ  nity for the target pepti-
doglycan (Malabarba and Ciabatti 2001; Streit et al 2004). 
Investigators hypothesize that these multiple mechanisms 
may contribute to dalbavancin’s rapid bactericidal activity 
against S. aureus (Finch et al 2005).
Pharmacokinetics
Dalbavancin possesses unique pharmacokinetic proper-
ties that distinguish it from other antimicrobial agents in 
the same class. The pharmacokinetics of dalbavancin are 
best described using a three-compartment model (α and 
β distributional phases followed by a terminal elimination 
phase). The distributional half-life (t1/2 β) that constitutes 
most of the clinically relevant concentration-time proﬁ  le 
ranged from 5 to 7 days and is consistent with once-weekly 
dosing (Pﬁ  zer Inc. 2007). Initial in vivo studies using rat 
and rabbit models found extended interval dosing effective, 
suggesting that human trials could potentially utilize weekly 
dosing schedules (Cavaleri et al 2005). Data from a Phase 
I investigation provided further support of dalbavancin’s 
once-weekly dosing regimen (Leighton et al 2004). In this 
trial, 52 healthy subjects were administered single parenteral 
doses of dalbavancin ranging from 140 mg to 1120 mg, and 
plasma drug concentrations were measured over time. Inves-
tigators observed that following administration there was a 
rapid decline in the plasma drug concentration in the ﬁ  rst 
24–48 hours, representing an initial distribution phase. This 
was followed by a longer elimination phase with a terminal 
half-life measuring from 123 to 210 hours (average of 181 
hours). Serum bactericidal activity was preserved against 
several MRSA strains tested, as plasma levels were noted 
to be greater than 20 µg/mL for 8 days in these subjectsTherapeutics and Clinical Risk Management 2008:4(1) 33
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following a 1000 mg dose. Additionally, in patients receiving 
a single dose of dalbavancin, the Cmax increased propor-
tionately with the administered dose; and linear regression 
analysis of Cmax and AUC versus the given dose demonstrated 
linear dose-proportional pharmacokinetics. Taken together, 
this investigation supplied data supporting a once-weekly 
dosing regimen (Leighton et al 2004).
Dalbavancin is highly protein bound (93%), primarily to 
albumin, which may account in part for its prolonged half-
life (Dowell et al 2005; Pope and Roecker 2006). Despite a 
small free fraction in serum, dalbavancin appears to dem-
onstrate bactericidal activity against S. aureus with MICs 
of 0.06 to 1.0 µg/mL (Bowker et al 2006). Dalbavancin 
demonstrates excellent tissue distribution and penetration in 
quantitative animal tissue distribution studies and in human 
trials (Leighton et al 2004; Cavaleri et al 2005; Nicolau et al 
2007). Maximum drug concentration is achieved in most 
tissues within 24 hours of administration with the highest 
concentrations in the kidney and liver (Cavaleri et al 2005). 
As demonstrated in a blister-model, dalbavancin appears to 
have excellent skin and soft-tissue penetration (Nicolau et al 
2007). Following a single 1000 mg dose in nine healthy vol-
unteers, the mean concentration of dalbavancin in plasma and 
blister ﬂ  uid at day seven was noted to be 46.5 µg/mL and 30.3 
µg/mL, respectively. These levels are well above the MICs for 
the pathogens associated with cSSTIs (Nicolau et al 2007).
Investigators have demonstrated that elimination of dal-
bavancin occurs by both renal and non-renal routes (Leigh-
ton et al 2004; Cavaleri et al 2005). This is in contrast to 
vancomycin and teicoplanin which are eliminated primarily 
by the kidney. In a Phase I trial, urine excretion of unaltered 
drug accounted for only 33.5% of the elimination of a single 
dose of dalbavancin which was similar to the 34.5% noted in 
an animal model (Leighton et al 2004; Cavaleri et al 2005). 
Additionally, mild renal impairment (creatinine clearance of 
50 to 80 ml/min) does not appear to alter dalbavancin’s phar-
macokinetic parameters (Dowell et al 2003). Nevertheless, 
data pertaining to side effects in patients with more severe 
renal impairment (creatinine clearance less than 50 ml/min) 
are lacking. Further studies are needed to assess the pharma-
cokinetic characteristics and side effects in these patients. In 
terms of hepatic clearance, dose adjustments do not appear to 
be required in patients with mild, moderate, or severe hepatic 
impairment (Dowell et al 2004; Andes and Craig 2007).
Pharmacodynamics
The pharmacodynamic properties of dalbavancin have been 
assessed in a neutropenic murine thigh and lung model 
(Andes and Craig 2007). While bacterial activity of older 
glycopeptides is not enhanced by higher drug concentrations 
above the MIC, dalbavancin has exhibited dose-dependent 
bactericidal activity against S. aureus. In a murine model 
developed by Andes et al, groups of mice were administered 
five different total doses of dalbavancin over six days 
(30 to 480 mg/kg for S. aureus) with several different dosing 
regimens (12–72 hours). Lengthening dosing intervals of 
dalbavancin appeared to improve treatment response indicat-
ing that the greatest efﬁ  cacy was obtained when larger doses 
were administered less frequently. The data obtained from 
this animal model supports the clinical use of higher and 
less frequent dosing in order to optimize treatment efﬁ  cacy 
(Andes and Craig 2007).
Spectrum of activity
Gram-positive activity
Dalbavancin appears to possess excellent activity against a 
wide range of gram-positive pathogens implicated in cSSTIs: 
staphylococci, streptococci, and enterococci, including 
VanB and VanC phenotypes of VRE (Candiani et al 1999; 
Goldstein et al 2003; Flamm et al 2004; Streit et al 2004; 
Jones et al 2005; Goldstein et al 2006b; Biedenbach et al 
2007). MIC data for dalbavancin against these organisms 
demonstrates favorable and generally lower ranges than 
those of vancomycin and other comparators (Candiani et al 
1999; Goldstein et al 2003; Flamm et al 2004; Streit et al 
2004; Jones et al 2005; Goldstein et al 2006b; Biedenbach 
et al 2007). Dalbavancin is also active against other gram-
positive pathogens including Bacillus spp., Corynebacterium 
spp., and Listeria spp. (Jones et al 2001; Goldstein et al 
2003; Streit et al 2004; Golstein et al 2006). Additionally, 
in some investigations, dalbavancin appears to be more 
rapidly bactericidal against gram-positive organisms than 
vancomycin or teicoplanin (Candiani et al 1999; Jones et al 
2001; Streit et al 2004).
Although no susceptibility breakpoints have been estab-
lished, dalbavancin appears to demonstrate excellent activity 
against staphylococci. MICs for MSSA, MRSA, and Coagu-
lase negative Staphylococcus (CoNS) range from 0.06 to 0.5 
µg/mL in most reports (Candiani et al 1999; Woodford 2003; 
Flamm et al 2004; Streit et al 2004; Jones et al 2005; Lin et al 
2005; Goldstein et al 2006b). Dalbavancin displays generally 
lower MICs against staphylococci when compared to other 
agents (Candiani et al 1999; Malabarba and Ciabatti 2001; 
Woodford 2003; Streit et al 2004; Lin et al 2005). Dalba-
vancin has been tested against several isolates with reduced 
susceptibility to vancomycin and has generally been shown Therapeutics and Clinical Risk Management 2008:4(1) 34
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to display decreased activity against these strains. Three 
VISA isolates tested against dalbavancin were noted to have 
MICs ranging from 1.0 to 4.0 µg/mL, and one VRSA isolate 
displayed a MIC of  0.5 µg/mL (Bozdogan et al 2003; Lefort 
et al 2004; Goldstein et al 2007). Despite evidence suggest-
ing less potency against VISA, the levels of dalbavancin 
obtained with a single 1000 mg dose should be adequate to 
achieve bactericidal activity (Leighton et al 2004). Impor-
tantly, dalbavancin retains activity against S. aureus strains 
with resistance to linezolid or quinupristin/dalfopristin 
(Jones et al 2003; Flamm et al 2004; Streit et al 2004; Streit 
et al 2005). Investigators assessing resistance development 
in staphylococci by both direct selection and serial passage 
have noted no stable mutants with decreased susceptibility 
to dalbavancin (Goldstein et al 2007). Overall, the bacteri-
cidal activity of dalbavancin at achievable concentrations in 
humans throughout the proposed dosing interval suggests 
a low potential for the selection of resistance in patients; 
however, this limited data may not apply to the susceptibili-
ties of colonizing strains exposed to prolonged post-therapy 
drug levels (Goldstein et al 2007).
Dalbavancin is highly active against all streptococci 
including S.pyogenes resistant to erythromycin and penicil-
lin (Candiani et al 1999; Jones et al 2001; Streit et al 2004; 
Flamm et al 2004; Streit et al 2005; Goldstein et al 2006a). 
Reported MICs of 0.015–0.06 µg/mL are also generally 
lower than those of vancomycin and other comparator agents 
(Candiani et al 1999; Jones et al 2001; Streit et al 2004; 
Flamm et al 2004; Streit et al 2005; Goldstein et al 2006a). 
Dalbavancin is active against vancomycin-susceptible 
enterococci and non-VanA VRE strains. Vancomycin-sus-
ceptible enterococci have demonstrated MICs comparable to 
S. aureus (0.06–0.5 µg/mL); however, dalbavancin appears 
to be slightly less active against Enterococcus faecium 
(MIC of 0.12 µg/mL) than Enterococcus faecalis (MIC of 
0.06 µg/mL) (Streit et al 2004). While the MICs for VanB 
and VanC VRE phenotypes range from 0.12 to 1 µg/mL, the 
MICs for dalbavancin against VanA enterococci are consid-
erably higher, ranging from 32 to greater than 128 µg/mL 
(Candiani et al 1999; Jones et al 2001; Jones et al 2003; Streit 
et al 2005). For enterococci with resistance to linezolid or 
quinopristin-dalfopristin, dalbavancin appears to display 
varrying activity depending on the individual strain (Jones 
et al 2003; Streit et al 2005). Taken together, dalbavancin 
appears to have excellent activity across the gram-positive 
spectrum of pathogens causing cSSTIs; however, one should 
not consider it as a practical therapy for gram-positive patho-
gens possessing the VanA gene.
Anaerobic and gram-negative activity
Dalbavancin demonstrates activity against most gram-
positive anaerobic pathogens although it remains inactive 
against most gram-negative anaerobic rods (Goldstein 
et al 2003; Goldstein et al 2006b). When compared to 
vancomycin, dalbavancin was found overall to be one to three 
dilutions more active in vitro against gram-positive anaerobes 
(Goldstein et al 2003). Similarly, in a study evaluating the 
effectiveness of dalbavancin against pre-treatment clinical 
isolates from diabetic foot infections, it was noted to be 
active against 120 anaerobic isolates with MICs ranging from 
less than 0.125 µg/mL to 0.5 µg/ml (Goldstein et al 2006b). 
Dalbavancin has no clinically relevant activity against gram-
negative bacteria (Jones et al 2001). Dalbavancin’s activity 
against gram-positive anaerobes may impart signiﬁ  cant 
clinical beneﬁ  t in the management of polymicrobial cSSTIs 
(Goldstein et al 2006b).
Animal studies
Dalbavancin has been studied extensively in animal models. 
These animal studies have demonstrated the effectiveness 
of dalbavancin in treating infections caused by a variety of 
gram-positive organisms and have helped deﬁ  ne appropri-
ate dosing regimens (Candiani et al 1999; Jabes et al 2004). 
Candiani et al employed both mouse and rat models in a 
multifaceted study to evaluate the use dalbavancin in sep-
ticemia, lobar pneumonia, and endocarditis (Candiani et al 
1999). In the septicemia arm of their investigation, MSSA and 
S. pneumoniae were used to infect immunocompetent mice, 
while S. epidermidis and E. faecalis were used in a group 
of immunocompromised mice. Outcomes were measured 
in terms of 50% protective efﬁ  cacy (ED50) against septice-
mia. Dalbavancin appeared to be slightly more active than 
vancomycin in the immunocompetent mice. In the immuno-
compromised mice infected with S. epidermidis, dalbavancin 
was by far the most active agent with a signiﬁ  cantly lower 
ED50; however, dalbavancin was slightly less active than 
teicoplanin against E. faecalis in the immunocompromised 
mice (Candiani et al 1999).
In the lobar pneumonia arm of this investigation, 
immunocompetent and neutropenic rats were infected with 
penicillin-susceptible and penicillin-resistant strains of 
S. pneumoniae (Candiani et al 1999). This pneumonia model 
demonstrated that animals that received dalbavancin had 
decreased bacterial load and better survival than those receiving 
3 days of penicillin-G regardless of penicillin susceptibility. 
Additionally, immunocompetent animals infected with a 
penicillin-resistant strain and treated with 10 mg/kg dalbavancin Therapeutics and Clinical Risk Management 2008:4(1) 35
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appeared to be the most efﬁ  cacious regimen when compared 
to controls (p   0.05) (Candiani et al 1999).
The ﬁ  nal arm of this investigation was a rat endocarditis 
model using MRSA and S. epidermidis (Candiani et al 1999). 
Animals were infected via a catheter placed in the left ventricle 
and were given either daily dalbavancin or twice daily van-
comycin or teicoplanin for a total of ﬁ  ve days. At the end of 
the study period and animal sacriﬁ  ce, colony counts were 
reported in terms of CFU/g of heart tissue. Daily dalbavancin 
(10 mg/kg/day) was the only antimicrobial regimen that 
resulted in signiﬁ  cantly more sterile samples when compared 
to untreated animals (p   0.05). In the S. epidermidis arm, 
drug regimens were similar in both outcomes and were both 
signiﬁ  cantly better than untreated controls (p   0.05). Overall, 
the results from this group of elaborate animal experiments 
demonstrated that dalbavancin was at least as effective as 
vancomycin or teicoplanin and provided results prompting 
further investigation (Candiani et al 1999).
LeFort et al also evaluated dalbavancin with a rabbit 
endocarditis model using S. aureus strains susceptible to 
vancomycin and teicoplanin (MICs of 2 and 4 µg/mL, 
respectively) and strains with reduced susceptibility to 
both glycopeptides (MICs of 8 and 16 µg/mL, respectively) 
(LeFort et al 2004). In this model, rabbits were infected with 
S. aureus and then treated with dalbavancin 10 mg/kg once 
daily for 4 days or with a single 40 mg/kg dose of the agent. 
Vegetation homogenates were plated and counted as CFU/g 
of vegetation. Both dalbavancin treatment groups obtained a 
signiﬁ  cant reduction in the colony count after therapy when 
compared to the untreated control group (p   0.01). Addi-
tionally, the once-daily dalbavancin dose was more effec-
tive than the single dose regimen. This endocarditis model 
provided evidence that dalbavancin has comparable activity 
to vancomycin against S. aureus with reduced glycopeptide 
susceptibility (LeFort et al 2004).
In another rabbit model, investigators compared the 
ability of dalbavancin and vancomycin to prevent S. aureus 
colonization of subcutaneously implanted intravenous 
catheters (Darouiche and Mansouri 2005). Investigators 
harvested these subcutaneously inserted catheters seven 
days after they had been implanted and inoculated 
with S. aureus. In this study, vancomycin performed 
no better than a saline control infusion in preventing 
catheter colonization. In contrast, dalbavancin prevented 
colonization in 28% of the catheters compared to 47% in 
the vancomycin-treated rabbits (p = 0.07). Although these 
results were not signiﬁ  cant, this study suggested that there 
may be a future role for dalbavancin in the prevention 
and treatment of device-related infection (Darouiche and 
Mansouri 2005).
In a rodent granuloma pouch model, investigators compared 
the activities of dalbavancin, linezolid, and vancomycin against 
experimental MSSA and MRSA bacterial infections (Jabes et al 
2004). In this study, suspensions of S. aureus were inoculated 
into rat granuloma pouches and antibiotic regimens were 
started shortly after infection. Aliquots of pouch exudates were 
removed, diluted, and plated in order to assess colony growth in 
terms of CFU/ml of exudate. In this set of experiments, single 
dose dalbavancin (2.5, 5, and 10 mg/kg doses) was compared 
to multiple doses of vancomycin or linezolid. Data from this 
study showed that dalbavancin was effective at reducing the 
bacterial load of MSSA at all doses when compared to the 
control group. Additionally, a dose-dependent reduction 
in MRSA bacterial load occurred with dalbavancin at the 
5 mg/kg and 10 mg/kg single doses. The single 10 mg/kg 
dalbavancin/kg dose reduced the viable MRSA count in 
pouch exudates by more than 2 log CFU/mL, and regrowth 
was prevented for up to 120 hours. To achieve comparable 
results with vancomycin, four 100-mg/kg intramuscular 
doses were needed. Data from this model demonstrated not 
only the efﬁ  cacy of single-dose dalbavancin, but also that it 
could be administered less frequently than both linezolid and 
vancomycin (Jabes et al 2004).
Clinical efﬁ  cacy
The safety and efﬁ  cacy of dalbavancin has been examined 
in three clinical trials (Seltzer et al 2003; Raad et al 2005; 
Jauregui et al 2005). These trials include: one Phase II inves-
tigation that examined tolerability and efﬁ  cacy in catheter-
related gram-positive bloodstream infections (CR-BSI) (Raad 
et al 2005); and two trials (one Phase II and one Phase III) that 
evaluated dalbavancin in the treatment of skin and soft-tissue 
infection (SSTI) (Seltzer et al 2003; Jauregui et al 2005).
Phase II trials
Seltzer et al first conducted an open label, randomized, 
controlled, Phase II multi-center trial examining one-dose 
and two-dose dalbavancin versus standard-of-care therapy 
for the treatment SSTI (Seltzer et al 2003). Standard-of-
care therapy was chosen prior to randomization by the 
investigators and included vancomycin, cephalosporins, 
clindamycin, piperacillin-tazobactam, or linezolid. If anaerobic 
or additional gram-negative antimicrobial coverage was 
thought necessary by investigators, patients could receive 
aztreonam, ceftazidime, or metronidazole. Clinical response 
was measured at day 10 for one-dose dalbavancin, at day 20 Therapeutics and Clinical Risk Management 2008:4(1) 36
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for two-dose dalbavancin, and on the last day of treatment 
for the comparator regimens. Additionally, patients were 
again assessed fourteen days following the completion of 
either therapy. Patients were excluded from the entry into the 
investigation for the following reasons: impaired renal function 
(creatinine clearance less than 50 mL/min), recent treatment 
for SSTI (within 7 days of study entry), self-limited infections, 
compromised vascularity, documented osteomyelitis, and 
history of vancomycin hypersensitivity (Seltzer et al 2003).
A total of 62 patients were enrolled in the study and 
received at least 1 dose of a study medication (Seltzer et al 
2003). The three treatment groups included: those receiving 
a single 1100 mg intravenous dose dalbavancin (20 patients); 
those receiving a 1000 mg dose of dalbavancin followed 
by a 500 mg dose seven days later (21 patients); and those 
receiving the comparator therapy which was administered for 
seven to twenty-one days (21 patients). Comparator regimens 
(standard-of-care of care) were determined by the investiga-
tors prior to randomization and included vancomycin, cepha-
losporins (ceftriaxone, cefazolin, cephalexin), clindamycin, 
piperacillin-tazobactam, and linezolid. Eleven patients were 
excluded from the clinically evaluable population for the 
following: requiring antimicrobial therapy for a non-SSTI 
or use of corticosteroids (5 patients); no evidence of a gram-
positive infection at baseline (3 patients); non-compliance 
with follow-up (2 patients), and SSTI with compromised 
vascular supply (1 patient). Approximately two-thirds of the 
patients enrolled in the investigation had undergone surgical 
intervention prior to randomization. The three study groups 
had similar success rates at the end of therapy and at the 
2-week follow-up visit. There was a trend toward a more 
favorable response in the two-dose dalbavancin group. In 
intention to treat analysis at the end of therapy, success rates 
were 91% (19 of 21) for two-dose dalbavancin, 75% (15 of 
20) for one-dose dalbavancin, and 81% (17 of 21) for the 
comparator group. Sixty-one organisms were cultured from 
42 patients in the microbiological intent to treat population 
with the majority (47 of 61 isolates) being S. aureus. Success 
rates for patients with MRSA infection were 80% (4 of 5) for 
two-dose dalbavancin, 50% (3 of 6) for one-dose dalbavancin 
and 50% (1 of 2) for the comparator group. A similar rate 
of success was noted in patients from whom streptococcal 
species were isolated. Failures in any of the groups were not 
explained by antibiotic resistance or lack of in vitro activ-
ity of the antimicrobial agent against the bacterial isolate 
(Seltzer et al 2003).
Investigators noted drug-related adverse events in 55% of 
patients in the one-dose dalbavancin group, 48% of patients in 
the two-dose dalbavancin group, and 57% in the comparator 
regimen group (Seltzer et al 2003). Of note, no patients 
receiving dalbavancin exited the study due to drug-related 
adverse events. Due to the investigation’s small sample 
size, no statistical analysis was reported; nevertheless, this 
study did provide human clinical evidence suggesting that 
two-dose dalbavancin could be effective in the treatment of 
SSTI (Seltzer et al 2003).
In another Phase II clinical trial, Raad et al evaluated the 
safety and efﬁ  cacy of dalbavancin for the treatment of CR-
BSI caused by gram-positive pathogens (Raad et al 2005). 
In this randomized, controlled, open-label multi-center trial, 
patients with presumed CR-BSI were assigned treatment with 
either two doses of dalbavancin (a 1000 mg dose on day one, 
followed by 500 mg on day 8) or vancomycin (1000 mg twice 
daily) for 14 days. Catheter removal was required for all cases 
of conﬁ  rmed S. aureus infection and recommended but not 
required for CoNS infection. Patients were excluded from 
the study if they had signiﬁ  cant renal or hepatic impairment, 
had received immunosuppressive therapy, had experienced 
prolonged neutropenia, had prior treatment with an antibiotic 
active against gram-positive organisms within 48 hours of 
initiation of the study medication, or had a pulmonary artery 
catheter. Investigators also excluded patients who had had 
S. aureus bacteremia during the previous three months thought 
to be from a non-catheter-related source (eg, endocarditis, 
osteomyelitis, infected prosthetic material, deep abscess, or 
septic thrombophlebitis). At the investigators’ discretion, a 
gram-negative active agent (aztreonam or ceftazidime) and 
an anaerobic active agent (metronidazole) were permitted 
based on clinical suspicion. The primary outcome measured 
was test-of-cure which was assessed by combining clinical 
and microbiologic response at a follow-up visit 18–24 days 
after completing therapy (Raad et al 2005).
Seventy-ﬁ  ve patients were enrolled in the investigation, 
67 of whom were included in the intent to treat popula-
tion (Raad et al 2005). With regard to CR-BSI etiology, 
54 bacterial isolates were recovered from 51 study patients. 
Of these 54 isolates, CoNS (26 isolates) was the most 
frequently isolated pathogen. S. aureus was the next most 
common pathogen (23 isolates), 14 of which were MRSA. 
Five E. faecalis isolates were also recovered. Overall, bac-
terial isolates did not appear to be signiﬁ  cantly different at 
baseline in the microbiologically conﬁ  rmed intent to treat 
population; however, more patients in the vancomycin group, 
32.1% (9 of 28 patients) had MRSA infection compared to 
19.2% (5 of 26 patients) in the dalbavancin group. In the 
microbiologic intent to treat analysis, overall success at the Therapeutics and Clinical Risk Management 2008:4(1) 37
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follow up visit was 87% (20 of 23) (95% CI: 73.2%–100%) 
for the dalbavancin group and 50% (14 of 28) (95% CI: 
31.5%–68.5%) for the vancomycin group. Microbiologic
success at the follow-up visit as deﬁ  ned by eradication 
or presumed eradication of the organism was 95.7% 
(22 of 23 patients) for those receiving dalbavancin and 78.6% 
(22 of 28 patients) for those receiving vancomycin (Raad 
et al 2003). A follow-up study subsequently characterized 
the blood isolates obtained from this trial (Goldstein et al 
2006a). The MIC results were less than 0.25 µg/mL for all 
of the isolates obtained from both groups, which included 
CoNS, S. aureus, and E. faecalis (Goldstein et al 2006a).
While these results appear to suggest signiﬁ  cant beneﬁ  t 
of dalbavancin over therapy with vancomycin, there are sev-
eral important limitations to this study. First, this study was 
designed only to assess safety and efﬁ  cacy of dalbavancin, 
not to determine superiority. Second, vancomycin (except in 
the case of signiﬁ  cant allergy) would be considered a second-
line agent for the treatment of MSSA bacteremia as it has 
been shown to be inferior to antistaphylococcal penicillins 
or ﬁ  rst-generation cephalosporins for the treatment of MSSA 
bacteremia (Chang et al 2003b; Stryjewski et al 2007). Third, 
interpretation of the data is made difﬁ  cult by the disparity in 
the number of MRSA-infected patients in each group (Raad 
et al 2003). Lastly, although the investigators used a stan-
dard dosing regimen, vancomycin serum drug levels were 
not reported; higher vancomycin levels may have altered 
outcome (Mohr and Murray 2007).
Phase III trials
In the only published Phase III investigation, Jauregui et al 
compared dalbavancin with linezolid for the treatment of 
cSSTIs (Jauregui et al 2005). In this double-blind, randomized, 
multicenter trial, 854 adult patients were enrolled with a 2:1 
randomization scheme. The 571 patients in the dalbavancin 
group received a 1000 mg dose on day one of therapy and 
a second dose of 500 mg on day 8. The 283 patients in the 
linezolid group received 600 mg twice daily for 14 days, with 
at least 24 hours of initial intravenous therapy. Investigators 
deﬁ  ned cSSTI as an infection that involved deeper soft-tissue, 
required signiﬁ  cant surgical intervention (eg, major abscess, 
major burns, surgical wound infection, and extensive or 
ulcerating cellulitis), or as a SSTI known or thought to be 
caused by MRSA. Additionally, patients were required to 
demonstrate at least two local signs and/or symptoms of 
cSSTI. Patients were excluded from participation if they had 
osteomyelitis, septic arthritis, were anticipated to require more 
than two surgical interventions during the study, or would 
require additional antimicrobial therapy for concomitant 
infections. Empiric use of aztreonam and/or metronidazole 
was permitted at the investigators’ discretion if a polymicrobial 
infection was suspected. The primary outcome measured was 
clinical success in all evaluable patients at a test-of-cure visit 
14 days (±2 days) after completing study medication. For 
study purposes, each dose of dalbavancin represented seven 
days of therapy (Jauregui et al 2005).
At baseline, there were no significant demographic 
differences between the two groups and they appeared to be 
well matched in terms of types of infection and underlying 
medical history (Jauregui et al 2005). At least one gram-
positive pathogen was recovered at baseline in 64% of 
patients. Ninety percent of the cultured isolates from each 
group were S. aureus (51% in each group were MRSA) and all 
remaining isolates were streptococcal species (Groups A, C, 
and G streptococcus, and Viridans streptococcus spp). Among 
patients who were clinically evaluable at the test-of-cure visit, 
the dalbavancin and linezolid groups achieved clinical success 
in 88.9% and 91.2%, respectively. Additionally, MRSA 
eradication rates at the test-of-cure visit were similar in both 
groups, with 91% cured in the dalbavancin group and 89% 
cured in the linezolid group. This investigation demonstrated 
that dalbavancin was well tolerated and as effective (non-
inferior) to linezolid in the treatment of cSSTIs. Additionally, 
dalbavancin exhibited excellent efﬁ  cacy against MRSA, 
suggesting that it could be an alternative to vancomycin 
or linezolid for patients in whom these agents would be 
contraindicated (Jauregui et al 2005).
Adverse events
Dalbavancin appears to be well tolerated in animal studies 
and in all clinical investigations. The clinical trials evaluating 
dalbavancin have not demonstrated any statistically signiﬁ  -
cant differences in adverse events in patients receiving dal-
bavancin versus comparator agents (Seltzer et al 2003; Raad 
et al 2005; Jauregui et al 2005). Indeed, there have been very 
few adverse reactions severe enough to result in termination 
of dalbavancin in any clinical trial to date. Neither ototoxity, 
nephrotoxicity, nor Red man syndrome has been described 
with dalbavancin therapy (Seltzer et al 2003; Jauregui et al 
2005; Raad et al 2005).
In a Phase I dose escalation study in healthy volunteers 
Leighton et al demonstrated no serious adverse events associ-
ated with dalbavancin administration (Leighton et al 2004). 
Additionally, in doses up to 1120 mg, no dose effect in terms 
of adverse events or laboratory abnormalities was noted. In 
this investigation, at least one treatment-associated adverse Therapeutics and Clinical Risk Management 2008:4(1) 38
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event was reported by 67% of the 39 study participants 
who received dalbavancin. In general, these adverse events 
were mild and did not result in study drug discontinuation. 
The most common events were subjective pyrexia (50%), 
headache (25%), and nausea (6%). Oral temperature did 
not exceed 37.5 ºC in any participant at any point during 
the study, and subjects in the placebo group reported similar 
reactions with regard to pyrexia (38%) and headache (31%). 
One subject developed an asymptomatic, transient, mild 
transaminitis (less than 5 times the upper limit of normal) 
following administration of 350 mg dalbavancin which was 
not noted in any subject receiving higher doses; and one 
subject in both the dalbavancin and placebo groups experi-
enced a transient mild hyperglycemia (Leighton et al 2004). 
Finally, no audiological changes or vestibular toxicity have 
been noted in any subjects receiving dalbavancin (Campbell 
et al 2003; Leighton et al 2004).
In a Phase II trial, Seltzer et al noted similar tolerability 
(Seltzer et al 2003). In this investigation dalbavancin-related 
adverse events were reported by 11 patients (55%) receiving 
single dose dalbavancin, 10 patients (48%) receiving 2 doses 
of dalbavancin, and 12 patients (57%) receiving the compara-
tor regimens. They found no clinically concerning laboratory 
abnormalities as a result of treatment in any treatment group. 
No patients discontinued dalbavancin nor left the study due 
to an adverse event (Seltzer et al 2003).
In a separate Phase II trial conducted by Raad et al where 
33 patients were administered 1000 mg of dalbavancin fol-
lowed by a 500 mg dose one week later, the most common 
treatment-related adverse events included: diarrhea (21%), 
hypotension (21%), constipation (18%), pyrexia (18%), and 
oral candidiasis (12%) (Raad et al 2005). Adverse events 
appeared to be more frequent in the dalbavancin group but 
were mild and did not lead to discontinuation of dalbavancin 
therapy or withdrawal from the study (Raad et al 2005).
Similar to other investigations, in a Phase III clinical trial 
comparing dalbavancin to linezolid for the treatment of cSSTIs, 
Jauregui et al reported mild side effects and good tolerability 
with dalbavancin therapy (Jauregui et al 2005). The most com-
mon dalbavancin-associated adverse events in this study were 
primarily gastrointestinal: nausea (3.2%), diarrhea (2.5%), 
and vomiting (1.9%). One serious adverse event was reported 
in the dalbavancin group, but this was considered not to be 
treatment related. This adverse event was a transient and mild 
leukopenia. Adverse events related to treatment were overall 
more frequent in the linezolid group (32.2%) than the dalba-
vancin group (25.4%) (Jauregui et al 2005). This trial along 
with the other preclinical and clinical trials has demonstrated 
that dalbavancin is well tolerated without signiﬁ  cant toxicity. 
It is important to remember that clinical studies have excluded 
patients who report a history of vancomycin or other glycopep-
tide allergy. Further clinical studies are needed to determine 
long term safety and drug effects.
Drug interactions
There has been a paucity of published data on drug-drug 
interactions with dalbavancin. An in vitro study evaluated 
combinations of dalbavancin with representatives of nine 
other classes of antimicrobial agents (oxacillin, gentami-
cin, clindamycin, levoﬂ  oxacin, rifampicin, vancomycin, 
quinupristin/dalfopristin, linezolid, and daptomycin) for 
antagonism and synergy against staphylococci, enterococci 
and streptococci, including resistant isolates (Johnson et al 
2006). The investigators detected no antagonism between 
dalbavancin and any of the other agents. Synergy was 
observed when dalbavancin was combined with oxacillin and 
tested against four strains of S. aureus; however, no synergy 
was observed with gentamicin (Johnson et al 2006). These 
in vitro observations warrant further investigation.
It is clear that non-renal mechanisms are important in 
the clearance of dalbavancin; however, there is no evidence 
suggesting that the cytochrome P450 enzyme system is 
involved in its metabolism (Leighton et al 2004; Buckwalter 
and Dowell 2005). A review of 532 patients who had received 
dalbavancin during several clinical trials noted that 79% had 
received concomitant medications that possessed a potential 
for signiﬁ  cant interaction through either inhibition or induc-
tion of the cytochrome P450 enzyme system (Buckwalter and 
Dowell 2005). These medications included: acetaminophen, 
aztreonam, fentanyl, metronidazole, furosemide, proton 
pump inhibitors, midazolam, and simvastatin. These classes 
of medications did not appear to clinically impact the clear-
ance of dalbavancin (Buckwalter and Dowell 2005).
Conclusion
The emergence of resistant pathogens responsible for cSSTIs 
in addition to increased clinical failures with vancomycin has 
driven the development of new antimicrobial agents. Dalba-
vancin is a novel parenterally administered semisynthetic 
lipoglycopeptide that possesses excellent activity against a 
wide range of gram-positive pathogens that cause cSSTIs. 
This agent’s unique pharmacokinetic profile, primarily 
attributed to its long half-life, allows for once-weekly dosing. 
Phase II and Phase III trials have demonstrated that dalba-
vancin is a safe, effective, and well-tolerated antimicrobial for 
the treatment of cSSTI. Its clinical effectiveness is enhanced Therapeutics and Clinical Risk Management 2008:4(1) 39
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by its once-weekly dosing. Once-weekly dosing may prove 
to be cost effective and clinically beneﬁ  cial in certain patient 
populations. The FDA is expected to approve dalbavancin in 
2008. At a time when new antimicrobials are needed, dalba-
vancin appears to be a promising new antimicrobial agent 
for the treatment of cSSTIs.
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